ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Procter and Gamble and HALEON side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Procter and GambleHALEON
studies on the registry8465
open to participants now010
phase 3 studies under way00
reach primary completion within a year09
programswith a study of their own in two years819

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseProcter and GambleHALEON
Phase 100%

HALEON: 15 of its 19 programs at phase 1

  1. Acetaminophenphase 1
  2. Advil Liqui-gels (Reference Product)phase 1
  3. Ibuprofenphase 1
  4. Regular Fluoride Toothpasteno phase
  5. Whitening Toothpasteno phase

and 10 more — sign in to see them all

79%
Phase 2

Procter and Gamble: 1 of its 8 programs at phase 2

  1. Sodium Fluoridephase 2
13%
00%
Phase 300%

HALEON: 2 of its 19 programs at phase 3

  1. ENO Limephase 3
  2. Stannous fluoride and Potassium nitrate Dentifricephase 3
11%
Approved, new studies

Procter and Gamble: 7 of its 8 programs at approved, new studies

  1. Tin Fluoridesapproved, new study
  2. Test Stannous Fluoride Dentifriceapproved, new study
  3. 0 ppm Fapproved, new study
  4. 1100 ppm as MFPapproved, new study
  5. 250 ppm F as MFPapproved, new study

and 2 more — sign in to see them all

88%

HALEON: 2 of its 19 programs at approved, new studies

  1. Fluticasoneapproved, new study
  2. Robitussin Maximum Strength Nighttime Cough DMapproved, new study
11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Procter and Gamble0 readouts · 0 phase 3············
HALEON3 readouts · 1 phase 3·

HALEON, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Fluticasoneapproved, new study · Dec 0 · NCT07817134
  2. Regular Fluoride Toothpasteno phase · Dec 0 · NCT07836998
  3. Whitening Toothpasteno phase · Dec 0 · NCT07836998
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Procter and Gamble

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

HALEON

New programs 3

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionProcter and GambleHALEON
Dental Plaqueboth · compare here

Procter and Gamble in Dental Plaque: 3 programs

  1. Sodium Fluoridephase 2
  2. Tin Fluoridesapproved, new study
  3. Cetylpyridiniumapproved, new study

Their studies: Procter and Gamble’s studies of Dental Plaque in search

HALEON in Dental Plaque: 5 programs

  1. Test Dentifriceno phase
  2. Test toothpasteno phase
  3. Dentifricesno phase
  4. Experimental Mouthwashno phase
  5. Test Fluoride Toothpasteno phase

Their studies: HALEON’s studies of Dental Plaque in search

Dentin Sensitivityboth · compare here

Procter and Gamble in Dentin Sensitivity: 2 programs

  1. Sodium Fluoridephase 2
  2. Tin Fluoridesapproved, new study

Their studies: Procter and Gamble’s studies of Dentin Sensitivity in search

Gingivitisboth · compare here

Procter and Gamble in Gingivitis: 4 programs

  1. Sodium Fluoridephase 2
  2. Tin Fluoridesapproved, new study
  3. Test Stannous Fluoride Dentifriceapproved, new study
  4. Cetylpyridiniumapproved, new study

Their studies: Procter and Gamble’s studies of Gingivitis in search

HALEON in Gingivitis: 2 programs

  1. Dentifricesno phase
  2. Sodium Bicarbonate Toothpasteno phase

Their studies: HALEON’s studies of Gingivitis in search

Tooth Discolorationboth · compare here

Procter and Gamble in Tooth Discoloration: 1 program

  1. Sodium Fluoridephase 2

Their studies: Procter and Gamble’s studies of Tooth Discoloration in search

HALEON in Tooth Discoloration: 2 programs

  1. Regular Fluoride Toothpasteno phase
  2. Whitening Toothpasteno phase

Their studies: HALEON’s studies of Tooth Discoloration in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Procter and Gamble 0 of 8 · HALEON 2 of 19 programs (2 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.